Structure Therapeutics Inc. American Depositary Shares (GPCR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.43B
Last updated: Nov 17, 2026 at 11:06 AM ET
Structure Therapeutics Inc. American Depositary Shares (GPCR) Stock Forecast
Analysts expect Structure Therapeutics Inc. American Depositary Shares (GPCR) to earn -$2.22 per share in the fiscal year ending Dec 31, 2026. Of 16 analysts, 15 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 16 ratings average 1.81, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 94% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 4 | 25.0% |
| Buy | 11 | 68.8% |
| Hold | 1 | 6.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 16
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Dec 31, 2026
- -$2.22
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$2.73
- EPS consensus, revenue $62500
- Fiscal year ending Dec 31, 2028
- -$1.61
- EPS consensus, revenue $186.40M
- Next report
- Feb 24, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$2.22 | -$2.26 to -$2.08 | 6 | N/A | N/A | 11 |
| Dec 31, 2027 | -$2.73 | -$3.21 to -$2.22 | 8 | $62500 | N/A | 8 |
| Dec 31, 2028 | -$1.61 | -$2.43 to $1.09 | 8 | $186.40M | $186.40M to $186.40M | 10 |
Quarterly Estimates
The EPS consensus falls from -$0.60 for the quarter ending Dec 31, 2026 to -$0.67 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.60 | -$1.24 to -$0.34 | 17 |
| Mar 31, 2027 | -$0.67 | -$0.71 to -$0.55 | 6 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 2 upward and 4 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 2 |
| Fiscal year ending Dec 31, 2027 | 1 | 2 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$1.62.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$2.22 | -$1.62 | -$1.62 | -$1.64 | -$1.62 | N/A |
| Fiscal year ending Dec 31, 2027 | -$2.73 | -$2.19 | -$2.19 | -$2.18 | -$2.19 | N/A |
| Quarter ending Mar 31, 2027 | -$0.67 | -$0.53 | -$0.53 | -$0.53 | -$0.54 | N/A |
Frequently Asked Questions About GPCR
What is the GPCR stock forecast?
Consensus analyst estimates put Structure Therapeutics Inc. American Depositary Shares's EPS at -$2.22 for the fiscal year ending Dec 31, 2026. The consensus rating from 16 analysts is Buy.
How do analysts rate GPCR stock?
Of 16 analysts covering Structure Therapeutics Inc. American Depositary Shares, 4 rate it Strong Buy, 11 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from GPCR next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.22, with estimates from -$2.26 to -$2.08 from 6 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.73, with estimates from -$3.21 to -$2.22 from 8 analysts.
What revenue do analysts expect from Structure Therapeutics Inc. American Depositary Shares next year?
For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $62500. For the fiscal year ending Dec 31, 2028, the consensus revenue estimate is $186.40M, with estimates from $186.40M to $186.40M.
How many analysts cover GPCR?
16 analysts rate Structure Therapeutics Inc. American Depositary Shares stock, and 6 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
GPCR pages: Overview, Earnings, Forecast, Financials, Competitors